A Sensitive Microscale HPLC-UV Method for the Determination of Doxofylline and its Metabolites in Plasma: An Adapted Method for Therapeutic Drug Monitoring in Children

Author(s): Yue-E Wu, Xiu-Fu Wu, Min Kan, Hai-Yan Shi, Meng-Jie Liu, Qian Dong, Xing-Kai Chen, Xin Huang, Yi Zheng*, Wei Zhao.

Journal Name: Current Pharmaceutical Analysis

Volume 16 , Issue 1 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Doxofylline (DXE) is a novel methylxanthine derivative used in the treatment of asthma and Chronic Obstructive Pulmonary Diseases (COPD). Therapeutic Drug Monitoring (TDM) has been proposed in adults, while the adapted analytical method and TDM data are still missing in children.

Methods: A highly sensitive and stability indicating High-Performance Liquid Chromatography (HPLC) method of DXE with caffeine as the internal standard, was developed and validated by separating its metabolites, β-Hydroxyethyltheophylline (HPE) and Theophylline (TPE). HPLC separation is achieved on C18 column connected to an ultraviolet detector (276 nm), using acetonitrile and ultra-pure water in a gradient mode of elution at a flow rate of 0.9 mL/min at 25°C. A liquid-liquid extraction method using ethyl acetate was developed with a small sample volume of plasma of 50 μL. Trough concentration was monitored in children receiving DXE therapy.

Results: The method was linear over the concentration ranges from 0.4-20 µg/mL for DXE, HPE and TPE, respectively, in plasma. The limits of quantification were 0.4 µg/mL. Intra- and interday coefficients of variation did not exceed 6.5%, and the accuracy ranged from 94.9% to 112.5%. A total of 39 children (mean age of 1.8 years, range: 0.3-5.7 years) were included. The pediatric patients had detectable DXE concentrations with a mean value of 1.78 µg/mL (range from 0.49 to 6.36 µg/mL), and HPE measurable concentrations with a mean value of 0.52 µg/mL (range from 0.40 to 0.82 µg/mL), while the TPE could not be measured in any patient.

Conclusion: A sensitive, reliable, and adapted HPLC method has been developed for the simultaneous analysis of DXE and its metabolites in children. The DXE and its metabolites trough concentrations showed large inter-individual variability.

Keywords: Doxofylline, high performance liquid chromatography, therapeutic drug monitoring, children,β- hydroxyethyltheophylline,theophylline.

[1]
Bologna, E.; Laganà, A.; Terracino, D.; Bolignari, P.; Biffignandi, P. Oral and intravenous pharmacokinetic profiles of doxofylline in patients with chronic bronchitis. J. Int. Med. Res., 1990, 18(4), 282-288.
[2]
Jian, G.U.; Zhang, C.; Cao, Z.; Yuzhen, L.I.; Chen, E. The pharmacokinetics of doxofylline in chinese. Chin. J. New Drugs, 2000, 9(6), 396-398.
[3]
Grosa, G.; Franzone, J.S.; Biglino, G. Metabolism of doxophylline by rat liver microsomes. Drug Metab. Dispos., 1986, 14(2), 267.
[4]
Franzone, J.S.; Cirillo, R.; Reboani, M.C. Pharmacological studies in animals of beta-hydroxyethyltheophylline, the major metabolite of doxofylline in humans. Methods Find. Exp. Clin. Pharmacol., 1991, 13(4), 289-299.
[5]
Lagana, A.; Bizzarri, M.; Marino, A.; Mancini, M. Solid phase extraction and high performance liquid chromatographic determination of doxophylline in plasma. Biomed. Chromatogr., 1990, 4(5), 205-207.
[6]
Gannu, R.; Bandari, S.; Sudke, S.G.; Rao, Y.M.; Shankar, B.P. Development and validation of a stability-indicating RP-HPLC method for analysis of doxofylline in human serum. application of the method to a pharmacokinetic study. Acta Chromatogr., 2007, 19(19), 149-160.
[7]
Bagnato, G.F. Tolerability of doxofylline in the maintenance therapy of pediatric patients with bronchial asthma. Eur. Rev. Med. Pharmacol. Sci., 1999, 3(6), 255-260.
[8]
Barnes, P.J.; Pauwels, R.A. Theophylline in the management of asthma: time for reappraisal? Eur. Respir. J., 1994, 7(3), 579-591.
[9]
Siddiqui, M.R.; Alothman, Z.A.; Rahman, N. Analytical techniques in pharmaceutical analysis: A review. Arab. J. Chem., 2017, 10(S1), S1409-S1421.
[10]
Rahman, N.; Azmi, S.N.H.; Wu, H.F. The importance of impurity analysis in pharmaceutical products: an integrated approach. Accredit. Qual. Assur., 2006, 11(1-2), 69-74.
[11]
Patil, P.S.; Hamrapurkar, P.D.; Phale, M.D.; Desai, M.I.; Pawar, S.B. Study of doxofylline and its degradation products in bulk drug by a newly developed stability-indicating HPLC method. J. AOAC Int., 2013, 96(4), 765-770.
[12]
Samanthula, G.; Yadiki, K.; Saladi, S.; Gutala, S.; Surendranath, K.V. Stability-indicating RP-HPLC method for the simultaneous estimation of doxofylline and terbutalinesulphate in pharmaceutical formulations. Sci. Pharm., 2013, 81(4), 969-982.
[13]
U.S Food & Drug Administration. Guidance for Industry Bioanalytical Method Validation. https://www.fda.gov/downloads/drugs/ guidancecomplianceregulatoryinformation/guidances/ucm368107. pdf (Accessed on: June 23, 2016)
[14]
Tagliaro, F.; Dorizzi, R.; Frigerio, A.; Marigo, M. Non-extraction HPLC method for simultaneous measurement of dyphylline and doxofylline in serum. Clin. Chem., 1990, 36(1), 113-115.
[15]
Bharathi, D.V.; Naidu, A.; Jagadeesh, B.; Laxmi, K.N.K.M.; Laxmi, P.R.N.; Reddy, P.R.; Mullangi, R. Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of zafirlukast, a selective leukotriene antagonist in human plasma: application to a clinical pharmacokinetic study. Biomed. Chromatogr., 2008, 22(6), 645-653.
[16]
Shukla, D.; Chakraborty, S.; Singh, S.; Mishra, B. Doxofylline: a promising methylxanthine derivative for the treatment of asthma and chronic obstructive pulmonary disease. Expert Opin. Pharmacother., 2009, 10(14), 2343-2356.
[17]
Wang, R.H.; Ju, H.S.; Huang, Q.H.; Xu, P. Simultaneous determination of theophylline,diprophylline and doxofylline in serum by HPLC. Chin J Hosp Phar., 2015, 35(21), 1921-1925.
[18]
Xu, Y.G.; Bo, Y.S.; He, Z.M.; Wang, C.Y.; Li, J.; Gao, Z.Y. Determination of doxofylline concentration in plasma by RP-HPLC. China Pharm., 2002, 08, 467-469.
[19]
Dini, F.L.; Cogo, R. Doxofylline: a new generation xanthine bronchodilator devoid of major cardiovascular adverse effects. Curr. Med. Res. Opin., 2001, 16(4), 258-268.
[20]
Barnes, P.J.; Pauwels, R.A. Theophylline in the management of asthma: time for reappraisal? Eur. Respir. J., 1994, 7(3), 579-591.


Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 16
ISSUE: 1
Year: 2020
Page: [47 - 54]
Pages: 8
DOI: 10.2174/1573412914666180611103849
Price: $65

Article Metrics

PDF: 12
HTML: 4